EDESA BIOTECH, INC. Operating Lease Cost
EDESA BIOTECH, INC. (EDSA) reported Operating Lease Cost of $17.89 thousand for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2025-12-12
- EDESA BIOTECH, INC. operating lease, cost for the quarter ending 2025-09-30 was $8.00, a 99.96% decline year-over-year.
- EDESA BIOTECH, INC. operating lease, cost for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- EDESA BIOTECH, INC. operating lease, cost for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- EDESA BIOTECH, INC. operating lease, cost for the quarter ending 2024-12-31 was $17.89K, a 11.09% decline year-over-year.
- EDESA BIOTECH, INC. operating lease, cost for fiscal 2025 was $17.89K, a 77.08% decline from fiscal 2024.
- EDESA BIOTECH, INC. operating lease, cost for fiscal 2024 was $78.07K, a 5.20% decline from fiscal 2023.
- EDESA BIOTECH, INC. operating lease, cost for fiscal 2023 was $82.36K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-09-30 | $8.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $8.00 derived: sum of 2 quarters · filed 2025-12-12 | $8.00 derived: sum of 3 quarters · filed 2025-12-12 | $17.89K 10-K · filed 2025-12-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 derived: sum of 2 quarters · filed 2025-08-08 | $17.89K 10-Q · filed 2025-08-08 | $36.75K derived: sum of 4 quarters · filed 2025-12-12 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | $17.89K 10-Q · filed 2025-05-14 | $36.75K derived: sum of 3 quarters · filed 2025-12-12 | $56.05K derived: sum of 4 quarters · filed 2025-12-12 |
| 2024-12-31 | $17.89K 10-Q · filed 2025-02-14 | $36.75K derived: sum of 2 quarters · filed 2025-12-12 | $56.05K derived: sum of 3 quarters · filed 2025-12-12 | $75.84K derived: sum of 4 quarters · filed 2025-12-12 |
| 2024-09-30 | $18.86K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $38.16K derived: sum of 2 quarters · filed 2025-12-12 | $57.96K derived: sum of 3 quarters · filed 2025-12-12 | $78.07K 10-K · filed 2025-12-12 |
| 2024-06-30 | $19.30K 10-Q · filed 2025-08-08 | $39.09K derived: sum of 2 quarters · filed 2025-08-08 | $59.21K 10-Q · filed 2025-08-08 | $80.04K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $19.79K 10-Q · filed 2025-05-14 | $39.91K 10-Q · filed 2025-05-14 | $60.74K derived: sum of 3 quarters · filed 2025-05-14 | $81.92K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $20.12K 10-Q · filed 2025-02-14 | $40.94K derived: sum of 2 quarters · filed 2025-02-14 | $62.13K derived: sum of 3 quarters · filed 2025-02-14 | |
| 2023-09-30 | $20.83K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-13 | $42.02K derived: sum of 2 quarters · filed 2024-12-13 | $82.36K 10-K · filed 2024-12-13 | |
| 2023-06-30 | $21.19K 10-Q · filed 2024-08-09 | $61.53K 10-Q · filed 2024-08-09 | ||
| 2021-06-30 | $20.89B 10-Q · filed 2021-08-13 | $20.89B derived: sum of 2 quarters · filed 2021-08-13 | ||
| 2021-03-31 | $20.25K 10-Q · filed 2021-05-14 | |||
| 2020-06-30 | $18.51B 10-Q · filed 2021-08-13 | $18.51B derived: sum of 2 quarters · filed 2021-08-13 | $57.08B 10-Q · filed 2021-08-13 | |
| 2020-03-31 | $19.13K 10-Q · filed 2021-05-14 | $38.57K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |